Bo Liang
Research Subjects
Bo Liang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Guoxin Du
IVIEW Therapeutics (Zhuhai Hengqin) Co., Ltd
2 shared publications- Amin Javer
University of British Columbia
1 shared publication - Bing Qin
Changsha Adesso Advanced Materials Co., Ltd., Changsha, China
1 shared publication - Chong Qiu
Medical School, Nantong University, 19 Qixiu Rd, Nantong, 226001, PR China
1 shared publication - Fei Ren
Nanfang Hospital, Southern Medical University
1 shared publication - Gang Wei
Department of Pharmaceutics School of Pharmacy Key Laboratory of Smart Drug Delivery (Fudan University) Ministry of Education National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers Fudan University Shanghai 201203 China
1 shared publication
Latest Publications
- 9 August 2026
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 31 (7) , 1126-1136
Development and preclinical evaluation of a copper-based acidic hydrogel for atopic dermatitis
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by impaired barrier function, immune dysregulation, and microbiota imbalance (Langan et al. 2020). It is one ...
- 9 August 2026
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 31 (7) , 1126-1136
Development and preclinical evaluation of a copper-based acidic hydrogel for atopic dermatitis
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by impaired barrier function, immune dysregulation, and microbiota imbalance (Langan et al. 2020). It is one ...
- Open Access
- 26 June 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1)
Recyclable glass fiber-reinforced epoxy copper clad laminates for printed circuit board
Epoxy-based copper-clad laminates (CCLs) comprise >60% of the rigid CCL market, yet such CCLs are rarely recyclable at present. This paper describes the first industrialization of recyclable epoxy systems prepared with acetal-functionalized methylenebis(oxy)dianilines (MDAs) degradable curing agents, which make the corresponding CCLs recyclable and reuseable. We systematically studied the curing behaviors as well as the thermal and mechanical properties of these recyclable epoxy systems. All epoxy/MDA systems thermally decomposed at >288 °C, enabling their CCLs to pass the thermal stress test-currently unachieved with vitrimers. The cured networks degraded in acid via acetal hydrolysis to linear polymers. FR-4-type CCLs cured with the three MDAs met all IPC-4101/128 requirements, and their degradation products were reused to prepare Composite Epoxy Material (CEM)-3-type CCLs: a circular life cycle. We industrialized 2,2'-MDA-cured FR-4, including printed circuit board application testing and qualification, scaled-up degradation and recycling in CEM-3, Underwriters Laboratories certification, and standardization.
- 26 June 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1)
Open AccessRecyclable glass fiber-reinforced epoxy copper clad laminates for printed circuit board
Epoxy-based copper-clad laminates (CCLs) comprise >60% of the rigid CCL market, yet such CCLs are rarely recyclable at present. This paper describes the first industrialization of recyclable epoxy systems prepared with acetal-functionalized methylenebis(oxy)dianilines (MDAs) degradable curing agents, which make the corresponding CCLs recyclable and reuseable. We systematically studied the curing behaviors as well as the thermal and mechanical properties of these recyclable epoxy systems. All epoxy/MDA systems thermally decomposed at >288 °C, enabling their CCLs to pass the thermal stress test-currently unachieved with vitrimers. The cured networks degraded in acid via acetal hydrolysis to linear polymers. FR-4-type CCLs cured with the three MDAs met all IPC-4101/128 requirements, and their degradation products were reused to prepare Composite Epoxy Material (CEM)-3-type CCLs: a circular life cycle. We industrialized 2,2'-MDA-cured FR-4, including printed circuit board application testing and qualification, scaled-up degradation and recycling in CEM-3, Underwriters Laboratories certification, and standardization.
- Open Access
In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations
To curb the spread of SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, we characterize the virucidal activity of long-acting Povidone Iodine (PVP-I) compositions developed using an in-situ gel forming technology. The PVP-I gel forming nasal spray (IVIEW-1503) and PVP-I gel forming ophthalmic eye drop (IVIEW-1201) rapidly inactivated SARS-CoV-2, inhibiting the viral infection of VERO76 cells. No toxicity was observed for the PVP-I formulations. Significant inactivation was noted with preincubation of the virus with these PVP-I formulations at the lowest concentrations tested. It has been demonstrated that both PVP-I formulations can inactivate SARS-CoV-2 virus efficiently in both a dose-dependent and a time-dependent manner. These results suggest IVIEW-1503 and IVIEW-1201 could be potential agents to reduce or prevent the transmission of the virus through the nasal cavity and the eye, respectively. Further studies are needed to clinically evaluate these formulations in early-stage COVID-19 patients.
Open AccessIn-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations
To curb the spread of SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, we characterize the virucidal activity of long-acting Povidone Iodine (PVP-I) compositions developed using an in-situ gel forming technology. The PVP-I gel forming nasal spray (IVIEW-1503) and PVP-I gel forming ophthalmic eye drop (IVIEW-1201) rapidly inactivated SARS-CoV-2, inhibiting the viral infection of VERO76 cells. No toxicity was observed for the PVP-I formulations. Significant inactivation was noted with preincubation of the virus with these PVP-I formulations at the lowest concentrations tested. It has been demonstrated that both PVP-I formulations can inactivate SARS-CoV-2 virus efficiently in both a dose-dependent and a time-dependent manner. These results suggest IVIEW-1503 and IVIEW-1201 could be potential agents to reduce or prevent the transmission of the virus through the nasal cavity and the eye, respectively. Further studies are needed to clinically evaluate these formulations in early-stage COVID-19 patients.